Stanford Inhibits 15-PGDH to Regrow Cartilage, Targeting 528 Million Osteoarthritis Cases
Updated
Updated · Okdiario · May 24
Stanford Inhibits 15-PGDH to Regrow Cartilage, Targeting 528 Million Osteoarthritis Cases
2 articles · Updated · Okdiario · May 24
Stanford researchers found that blocking the aging-linked protein 15-PGDH regenerated knee cartilage in older mice, with treated animals moving more normally and bearing more weight on the affected leg.
Twice-weekly dosing for 4 weeks also blunted post-injury osteoarthritis in younger mice after ACL-like damage, a notable result because about 50% of people develop osteoarthritis within 15 years of such tears.
Human cartilage taken from knee-replacement patients responded after 1 week in the lab, showing less breakdown and signs of articular cartilage regeneration as existing chondrocytes shifted into a repair mode.
The work remains preclinical: no 15-PGDH therapy is approved for osteoarthritis, though a prior Phase 1 trial of an inhibitor for muscle weakness found it safe and biologically active in healthy volunteers.
Published in Science, the study points to a possible shift from symptom control to tissue repair in a disease that affected an estimated 528 million people worldwide in 2019.
This discovery promises to regenerate our own cartilage. How long until an injection can truly reverse years of osteoarthritis damage?
With multiple breakthroughs in cartilage repair, which new drug will actually be the first to make joint replacement surgery obsolete?
If a new drug can reverse joint aging, what are the hidden risks of turning off the body's master aging 'brake'?
15-PGDH Inhibition: A Breakthrough Approach to Cartilage Regeneration and Osteoarthritis Treatment
Overview
Stanford Medicine has introduced a groundbreaking approach to osteoarthritis by focusing on the protein 15-PGDH, which naturally increases as we age and contributes to tissue decline. Unlike current treatments that only manage pain or require joint replacement, this new therapy targets and blocks 15-PGDH, aiming to regenerate damaged cartilage and restore joint function. By identifying 15-PGDH as a 'gerozyme' that drives tissue aging, researchers have opened a promising path to treat the root cause of osteoarthritis, offering hope for millions who suffer from this condition.